Aim: To evaluate the influence of (11)C-choline PET/CT on radiotherapy planning in prostate cancer patients.
Background: Precise information on the extension of prostate cancer is crucial for the choice of an appropriate therapeutic strategy. (11)C-choline positron emission tomography ((11)C-choline PET/CT) has two roles in radiation oncology (RT): (1) patient selection for treatment and (2) target volume selection and delineation. In conjunction with high-accuracy techniques, it might offer an opportunity of dose escalation and better tumour control while sparing healthy tissues.
Materials And Methods: We carried out a retrospective study in order to analyse RT planning modification based on (11)C-choline PET/CT in 16 prostate cancer patients. Patients were treated with hypofractionated step-and-shoot Intensity Modulated Radiotherapy (IMRT), or Volumetric Modulated Arc Therapy (VMAT), and a daily cone-beam CT for Image Guided Radiation Therapy (IGRT). All patients underwent a (11)C-choline-PET/CT scan prior to radiotherapy.
Results: In 37.5% of cases, a re-delineation and new dose prescription occurred. Data show good preliminary clinical results in terms of biochemical control and toxicity. No gastrointestinal (GI)/genitourinary (GU) grade III toxicities were observed after a median follow-up of 9.5 months.
Conclusions: In our experience, concerning the treatment of prostate cancer (PCa), (11)C-choline PET/CT may be helpful in radiotherapy planning, either for dose escalation or exclusion of selected sites.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338287 | PMC |
http://dx.doi.org/10.1016/j.rpor.2014.11.008 | DOI Listing |
Medicine (Baltimore)
September 2024
Department of Radiology, Mayo Clinic, Rochester, MN.
J Endocrinol Invest
October 2024
Nuclear Medicine Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di S. Orsola, Via Albertoni 15, Bologna, Italy.
Background: In recent years, nuclear medicine imaging methods have proven to be of paramount importance in a wide variety of diseases, particularly in oncology, where they are crucial for assessing the extent of disease when conventional methods fall short. Moreover, nuclear imaging modalities are able to better characterize lesions using target agents related to specific pathways (e.g.
View Article and Find Full Text PDFJ Cancer
February 2024
Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun 130033, China.
To compare the diagnostic efficacy of C-choline PET/CT, neck ultrasonography, Tc-MIBI dual-phase planar scintigraphy, and Tc-MIBI SPECT/CT imaging in the diagnosis of primary hyperparathyroidism (PHPT). We conducted a retrospective analysis of 32 patients with PHPT who visited the Nuclear Medicine Department of Jilin University China-Japan Union Hospital between January 2019 and December 2022. All patients underwent C-choline PET/CT, neck ultrasonography, Tc-MIBI dual-phase planar scintigraphy, and Tc-MIBI SPECT/CT examinations within two months before surgery.
View Article and Find Full Text PDFNucl Med Mol Imaging
February 2024
Nuclear Medicine Department, S. Croce e Carle Hospital, Cuneo, Italy.
A 79-year-old man with prostate cancer (PCa) was referred to our center to perform a [C]Choline PET/CT for biochemical recurrence. Positron emission tomography/computed tomography (PET/CT) scan detected PCa recurrence in the prostate gland and several pelvic and abdominal lymph nodes. Two abnormal uptakes were also identified in the right breast and in the liver, respectively.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
January 2024
Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Aims: To report long-term outcomes of relapsed prostate cancer (PC) patients treated in a prospective single-arm study with extended-nodal radiotherapy (ENRT) and [11C]-choline positron emission tomography (PET)/computed tomography (CT)-guided simultaneous integrated boost (SIB) to positive lymph nodes (LNs).
Methods: From 12/2009 to 04/2015, 60 PC patients with biochemical relapse and positive LNs only were treated in this study. ENRT at a median total dose (TD) = 51.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!